Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF – Get Free Report) was the recipient of a large decrease in short interest in the month of June. As of June 30th, there was short interest totaling 191,938 shares, a decrease of 35.0% from the June 15th total of 295,188 shares. Based on an average daily volume of 20 shares, the short-interest ratio is currently 9,596.9 days. Currently, 0.1% of the company’s stock are short sold.
Recordati Industria Chimica E Farmaceutica Price Performance
Shares of OTCMKTS RCDTF opened at $58.00 on Friday. Recordati Industria Chimica E Farmaceutica has a 12-month low of $55.88 and a 12-month high of $60.00. The company has a market cap of $11.97 billion, a P/E ratio of 21.94 and a beta of 0.25. The company has a current ratio of 1.26, a quick ratio of 0.86 and a debt-to-equity ratio of 0.85. The stock has a fifty day moving average price of $58.33 and a 200 day moving average price of $59.87.
Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported $1.08 EPS for the quarter. The company had revenue of $834.86 million for the quarter. Recordati Industria Chimica E Farmaceutica had a return on equity of 34.38% and a net margin of 17.81%.
Recordati Industria Chimica E Farmaceutica Company Profile
Recordati Industria Chimica e Farmaceutica is an Italy?based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.
The company’s historical roots date back nearly a century, when it began as a family?owned enterprise in Milan.
Featured Stories
- Five stocks we like better than Recordati Industria Chimica E Farmaceutica
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Recordati Industria Chimica E Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica E Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
